Targeting NMNAT1 to Axons and Synapses Transforms Its Neuroprotective Potency In Vivo
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Axon and synapse degeneration are common components of many neurodegenerative diseases, and their rescue is essential for effective neuroprotection. The chimeric Wallerian degeneration slow protein (Wld S) protects axons dose dependently, but its mechanism is still elusive. We recently showed that Wld S acts at a non-nuclear location and is present in axons. This and other recent reports support a model in which Wld S protects by extranuclear redistribution of its nuclear NMNAT1 portion. However, it remains unclear whether cytoplasmic NMNAT1 acts locally in axons and synapses or at a non-nuclear site within cell bodies. The potency of axon protection by non-nuclear NMNAT1 relative to Wld S also needs to be established in vivo. Because the N-terminal portion of Wld S(N70) localized to axons, we hypothesized that it mediates the trafficking of the NMNAT1 portion. To test this, we substituted N70 with an axonal targeting peptide derived from amyloid precursor protein, and fused this to NMNAT1 with disrupted nuclear targeting. In transgenic mice, this transformed NMNAT1 from a molecule unable to inhibit Wallerian degeneration, even at high expression levels, into a protein more potent than Wld S, able to preserve injured axons for several weeks at undetectable expression levels. Preventing NMNAT1 axonal delivery abolished its protective effect. Axonally targeted NMNAT1 localized to vesicular structures, colocalizing with extranuclear Wld S, and was cotransported at least partially with mitochondria. We conclude that axonal targeting of NMNAT activity is both necessary and sufficient to delay Wallerian degeneration, and that promoting axonal and synaptic delivery greatly enhances the effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imaging Neuronal Subsets in Transgenic Mice Expressing Multiple Spectral Variants of GFP
Feng, G., Mellor, R. H., Bernstein, M., Keller-Peck, C., Nguyen, Q. T., Wallace, M., Nerbonne, J. M., Lichtman, J. W., & Sanes, J. R. (2000) · Neuron · doi:10.1016/s0896-6273(00)00084-2 · Cited by 3,042
Mitofusin 2 tethers endoplasmic reticulum to mitochondria
de Brito, O. M., & Scorrano, L. (2008) · Nature · doi:10.1038/nature07534 · Cited by 2,442 · cited 1×
“In this context, it is interesting to note evidence for physical connection between ER and mitochondria (de Brito and Scorrano, 2008).”
BackgroundIncreased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060 · cited 3×
“Because enzymatic NMNAT activity is essential for Wld S neuroprotection (Araki et al., 2004; Jia et al., 2007; Conforti et al., 2009; Sasaki et al., 2009a) and measurements of NMNAT enzyme activity also allow quantitative assessment of transgenic protein levels (Conforti et al., 2007; Beirowski et…”
BackgroundAxon degeneration mechanisms: Commonality amid diversity
Coleman, M. (2005) · Nature reviews. Neuroscience · doi:10.1038/nrn1788 · Cited by 819 · cited 3×
“This is particularly important for pathologies in which synapses are affected at early stages, such as amyotrophic lateral sclerosis (ALS).”
BackgroundSelf-citationAbsence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646 · cited 1×
“Studies of the mutant mouse Wld S (Wallerian degeneration slow) (Lunn et al., 1989) established axonal degeneration as a tightly regulated process.”
BackgroundWallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
Self-citationKang, J.-S., Tian, J.-H., Pan, P.-Y., Zald, P., Li, C., Deng, C., & Sheng, Z.-H. (2008) · Cell · doi:10.1016/j.cell.2007.11.024 · Cited by 598 · cited 2×
“Velocity of mitochondria movement was similar in transfected and untransfected neurons with pauses between continuous transport (supplemental Movie 2, available at www. jneurosci.org as supplemental material), as described previously (Takenaka et al., 1990; Kang et al., 2008).”
BackgroundMethodKamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., & Goldstein, L. S. B. (2001) · Nature · doi:10.1038/414643a · Cited by 583 · cited 2×
“Although a direct interaction between APP and kinesin is controversial (Kamal et al., 2001; Lazarov et al., 2005), the exit of vesicles containing APP from the trans-Golgi-network is mediated by calsyntenin-1 (Ludwig et al.”
BackgroundBerger, F., Lau, C., Dahlmann, M., & Ziegler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508660200 · Cited by 508
Endogenous Nmnat2 Is an Essential Survival Factor for Maintenance of Healthy Axons
Gilley, J., & Coleman, M. P. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000300 · Cited by 472 · cited 2×
“We recently identified NMNAT2 as a survival factor in wild-type axons (Gilley and Coleman, 2010).”
BackgroundMethodSelf-citationConforti, L., Tarlton, A., Mack, T. G. A., Mi, W., Buckmaster, E. A., Wagner, D., Perry, V. H., & Coleman, M. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11377 · Cited by 251
Self-citationAxonal Transport, Amyloid Precursor Protein, Kinesin-1, and the Processing Apparatus: Revisited
Lazarov, O., Morfini, G. A., Lee, E. B., Farah, M. H., Szodorai, A., DeBoer, S. R., Koliatsos, V. E., Kins, S., Lee, V. M.-Y., Wong, P. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3089-04.2005 · Cited by 239
Ferri, A., Sanes, J. R., Coleman, M. P., Cunningham, J. M., & Kato, A. C. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00206-9 · Cited by 221
Self-citationDrosophila NMNAT Maintains Neural Integrity Independent of Its NAD Synthesis Activity
Zhai, R. G., Cao, Y., Hiesinger, P. R., Zhou, Y., Mehta, S. Q., Schulze, K. L., Verstreken, P., & Bellen, H. J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040416 · Cited by 166 · cited 6×
“Wld S would not be expected to delay denervation of NMJs at these expression levels, as motor nerve terminals in Wld S heterozygotes are not preserved following axotomy even at 1–2 months of age (Wong et al., 2009).”
BackgroundInfluentialYahata, N., Yuasa, S., & Araki, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4304-08.2009 · Cited by 154 · cited 3×
“A mitochondrial involvement in the mechanism of WldS and NMNAT1 protection would be in line with recent findings showing that mitochondrial NMNAT3 protects in vivo (Yahata et al., 2009).”
BackgroundResultTransgenic Mice Expressing the Nmnat1 Protein Manifest Robust Delay in Axonal Degeneration In Vivo
Sasaki, Y., Vohra, B. P. S., Baloh, R. H., & Milbrandt, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1429-09.2009 · Cited by 152
Wlds-Mediated Protection of Dopaminergic Fibers in an Animal Model of Parkinson Disease
Sajadi, A., Schneider, B. L., & Aebischer, P. (2004) · Current Biology · doi:10.1016/j.cub.2004.01.053 · Cited by 142 · cited 2×
“…various neurodegenerative conditions, such as progressive motor neuronopathy, Charcot– Marie–Tooth disease, Parkinson’s disease, and glaucoma (Ferri et al., 2003; Samsam et al., 2003; Sajadi et al., 2004; Howell et al., 2007; Beirowski et al., 2008), opening new avenues for therapeutic approaches.”
BackgroundMi, W. (2004) · Brain · doi:10.1093/brain/awh368 · Cited by 115
Polarized targeting of neurexins to synapses is regulated by their C-terminal sequences
Fairless, R., Masius, H., Rohlmann, A., Heupel, K., Ahmad, M., Reissner, C., Dresbach, T., & Missler, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5294-07.2008 · Cited by 91
Cited by
Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury
Gaudet, A. D., Popovich, P. G., & Ramer, M. S. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-110 · Cited by 895
Wallerian degeneration: an emerging axon death pathway linking injury and disease
Conforti, L., Gilley, J., & Coleman, M. P. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3680 · Cited by 611
Self-citationAxon degeneration: Molecular mechanisms of a self-destruction pathway
Wang, J. T., Medress, Z. A., & Barres, B. A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201108111 · Cited by 442
Nickells, R. W., Howell, G. R., Soto, I., & John, S. W. M. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.051508.135728 · Cited by 336
Programmed axon degeneration: from mouse to mechanism to medicine
Coleman, M. P., & Höke, A. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0269-3 · Cited by 321
Self-citation
Metadata
- Authors
- Babetto, E., Beirowski, B., Janeckova, L., Brown, R., Gilley, J., Thomson, D., Ribchester, R. R., & Coleman, M. P.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-10-06
- Volume
- 30
- Issue
- 40
- Pages
- 13291-13304
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2066326400
- Cited by
- 119
- References
- 19
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.